Analyst Ratings February 13, 2026

Baird Boosts Synchrony Financial to Outperform, Citing Valuation and Credit Strength

Analyst raises price target to $83 as recent sell-off creates what the firm views as an attractive entry point for investors

By Maya Rios SYF
Baird Boosts Synchrony Financial to Outperform, Citing Valuation and Credit Strength
SYF

Baird upgraded Synchrony Financial from Neutral to Outperform and set an $83.00 price target, pointing to attractive valuation metrics, resilient credit trends and capital flexibility. The firm highlighted risk-sharing agreements and a strong CET1 ratio as buffers against possible credit deterioration, while recent quarterly revenue shortfalls and regulatory risk remain near-term considerations.

Key Points

  • Baird upgraded Synchrony from Neutral to Outperform and set an $83.00 price target; analyst targets range from $71 to $103. Impacted sectors: consumer finance and broader financials.
  • Synchrony’s CET1 ratio is around 12.6% and the company has risk-sharing agreements that Baird sees as a macro hedge; management has been active in share buybacks and the dividend yield is 1.69%. Impacted sectors: banking, credit-card lending.
  • Valuation after the sell-off is modest by historical standards - roughly 1.9x tangible book, 7.6x 2026 estimated earnings, P/E 7.66 and PEG 0.83 - which led Baird to view the pullback as a buying opportunity. Impacted markets: equity investors in financial stocks.

Baird elevated its rating on Synchrony Financial from Neutral to Outperform on Friday and assigned a price target of $83.00. That target implies material upside relative to the stock's recent level of $71.11, with analyst targets reported between $71 and $103.

The upgrade follows a period of weakness across consumer finance names, which Baird interprets as creating a favorable buying window. The firm pointed to solid pre-provision net revenue trends and credit metrics that have been supported by continuing positive employment dynamics.

Data on the company’s financial profile show a strong financial health score of 3.18, described as "GREAT," with particularly robust marks for profitability. Baird singled out Synchrony’s risk-sharing agreements as a meaningful macro hedge that should help mitigate the impact of any credit deterioration.

On capital strength, Synchrony reported a Common Equity Tier 1 (CET1) ratio of about 12.6%, a level Baird judges sufficient to sustain aggressive shareholder returns. Management has been actively repurchasing shares and the company also pays a dividend yield of 1.69%, with dividend growth of 20% over the past twelve months.

Valuation metrics look relatively inexpensive in Baird’s view after the recent market sell-off. The bank highlighted that Synchrony trades at approximately 1.9 times tangible book value and about 7.6 times 2026 estimated earnings. Current market measures include a P/E ratio of 7.66 and a PEG ratio of 0.83, indicating a low earnings multiple relative to growth expectations.

Baird also weighed in on regulatory concerns that have circulated among market participants, specifically the possibility of a caps on card APRs. The firm considers the implementation of a 10% card APR cap to be "highly unlikely without significant changes to consumer lending dynamics." That view, combined with a reported return on equity of 22% and strong profitability metrics, underpins Baird’s assessment that Synchrony is well-positioned to absorb potential regulatory shifts.

Investors will also be digesting the company’s latest quarterly results, which delivered mixed signals. For the fourth quarter of 2025 Synchrony reported net earnings of $751 million, or $2.04 per diluted share, which met consensus EPS expectations. Revenue, however, totaled $3.79 billion versus an anticipated $3.84 billion, creating a revenue shortfall that has drawn investor attention.

The revenue miss has become a focal point for market observers, even as earnings per share met projections. Baird’s upgrade frames the sell-off associated with these and other sentiment drivers as an opportunity, given the combination of valuation, capital position and credit metrics.

For market participants, the immediate takeaway from the research note is that Synchrony’s risk-sharing arrangements and capital cushions are viewed as important defenses. At the same time, the quarter’s revenue shortfall and ongoing regulatory chatter remain tangible near-term uncertainties that could influence investor sentiment.


Summary

Baird moved Synchrony Financial to an Outperform rating with an $83 price target, citing attractive valuation after a pullback, solid pre-provision net revenue trends, supportive credit metrics and a strong capital position. The firm views regulatory action to cap card APRs as unlikely in the absence of major changes to consumer lending dynamics. Recent fourth-quarter results met EPS expectations but missed on revenue.

Risks

  • Regulatory uncertainty related to potential caps on card APRs; while Baird deems a 10% APR cap unlikely without major shifts in consumer lending, regulatory action remains a possible risk. Affected sectors: consumer finance and credit-card lending.
  • Recent revenue shortfall in Q4 2025 - reported revenue of $3.79 billion missed expectations of $3.84 billion - which has raised concerns among investors despite EPS meeting estimates. Affected markets: investors focused on company revenue trends and earnings quality.
  • Market volatility and sector-wide weakness in consumer finance stocks could continue to pressure valuation and investor sentiment even if credit metrics remain sound. Affected sectors: financials and equity markets for consumer credit providers.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026